Assessment of Ovarian Reserve Tests in Unexplained Infertile Women

NCT ID: NCT02127944

Last Updated: 2018-12-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

80 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-04-30

Study Completion Date

2015-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

IN UNEXPLAINED INFERTILITY IN WOMEN ,OVARY RESERVE IS BORDERLINE IF ASSESSED USING HIGH-SENSITIVE TESTS.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

IN UNEXPLAINED INFERTILITY OVARIAN RESERVE TESTS WERE ASSESSED.

IN THIS STUDY, A COMPARISON IS DONE BETWEEN 35 WOMEN WITH UNEXPLAINED FERTILITY(THE PATIENT) AND 35 WOMEN WHO DON'T HAVE ANY FERTILITY PROBLEMS AND HAVE AT LEAST A CHILD (THE CONTROL GROUP).

THE STUDY PARTICIPANTS SHOULD HAVE THE FOLLOWING CRITERIA

Inclusion Criteria:

LESS THAN 35 YEARS OLD, MARRIED WOMEN SHOULD HAVE REGULAR MENSES SHOULD HAVE AT LEAST A YEAR OF UNPROTECTED SEX. THE HUSBAND'S SPERMOGRAM SHOULD HAVE NO ABNORMALITIES THE SUBJECT SHOULD HAVE A NORMAL HYSTEROSALPHINGOGRAPHY

Exclusion Criteria:

HAVING ANY SYSTEMIC DISEASE. LONG HISTORY OF ANY DRUG USAGE.

FOR THE CONTROL GROUP

Inclusion Criteria:

LESS THAN 35 YEARS OLD, MARRIED WOMEN SHOULD HAVE REGULAR MENSES AT LEAST HAVE A CHILD THE HUSBAND'S SPERMOGRAM SHOULD HAVE NO ABNORMALITIES THE SUBJECT SHOULD HAVE A NORMAL HYSTEROSALPHINGOGRAPHY

Exclusion Criteria:

HAVING ANY SYSTEMIC DISEASE. LONG HISTORY OF ANY DRUG USAGE.

THE STUDY INCLUDES THE FOLLOWING TESTS BEING DONE ON THE PATIENTS:

THE FOLLOWING HORMONES' LEVELS WERE STUDIED:AMH (ANTI-MULLERIAN HORMONE),FSH (FOLLICULAR STIMULATING HORMONE) , E2 (ESTRADIOL) AND INHIBIN B.THE FORMER THREE HORMONE LEVELS SHOULD BE ASSESSED ON THE THIRD DAY OF MENSES IN THE STUDY,TRANSVAGINAL ULTRASONOGRAPHIC OVARIAN VOLUME ,OVARIAN ANTRAL FOLLICULE NUMBER,OVARIAN STROMAL BLOODFLOW AND OVARIAN ARTERIAL RESISTANCE WAS MEASURED USING DOPPLER ULTRASONOGRAM.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Infertility Infertility, Female

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

FERTILE GROUP

WOMEN HAVE NO INFERTILITY PROBLEMS AND HAVE AT LEAST ONE CHILD

No interventions assigned to this group

UNEXPLAINED INFERTILE GROUP

WOMEN WITH INFERTILITY PROBLEMS,NO HISTORY OF PREGNANCY AND HAVE NO CHILDREN

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* LESS THAN 35 YEARS OLD,
* MARRIED WOMEN
* SHOULD HAVE REGULAR MENSES
* SHOULD HAVE AT LEAST A YEAR OF UNPROTECTED SEX.

Exclusion Criteria

* HAVING ANY SYSTEMIC DISEASE.
* LONG HISTORY OF ANY DRUG USAGE.
Minimum Eligible Age

21 Years

Maximum Eligible Age

35 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Karadeniz Technical University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Suleyman Guven

Assıstant. Professor.

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

SULEYMAN GUVEN

Role: PRINCIPAL_INVESTIGATOR

KARADENIZ TECHNICAL UNIVERSITY -MEDICAL FACULTY

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ktu Farabi Hospital

Trabzon, , Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MS1

Identifier Type: -

Identifier Source: org_study_id